Online citations, reference lists, and bibliographies.
← Back to Search

Expression Of The Immune Checkpoint VISTA In Breast Cancer

Liju Zong, Shengwei Mo, S. Yu, Y. Zhou, M. Zhang, J. Chen, Y. Xiang
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint that is an emerging target for cancer immunotherapy. This study aimed to investigate the expression of VISTA and its association with clinicopathologic parameters as we N ll as with the key immune markers including programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1) in invasive ductal carcinoma (IDC) of the breast. Immunohistochemistry was used to detect VISTA, PD-1, PD-L1, and CD8 in tissue microarrays from 919 patients with IDC ( N  = 341 in the exploratory cohort and  = 578 in the validation cohort). VISTA was expressed on the immune cells of 29.1% (267/919) of the samples and on the tumor cells of 8.2% (75/919). VISTA was more frequently expressed in samples that were estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2-positive, poorly differentiated, human epidermal growth factor receptor 2-enriched, and consisting of basal-like tumors. VISTA on immune cells correlated with PD-1, PD-L1, stromal CD8, and tumor-infiltrating lymphocyte expression and was an independent prognostic factor for improved relapse-free and disease-specific survival in patients with estrogen receptor-negative, progesterone receptor-negative, and basal-like IDC. These findings support therapeutic strategies that modulate VISTA expression, perhaps in combination with PD-1/PD-L1 blockade, in human breast cancer immunotherapy.
This paper references
10.1038/modpathol.2017.89
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
10.1007/s10549-016-3717-z
HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
Yao-Shan Fan (2016)
10.1093/ANNONC/MDX376.007
1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
J. D. Powderly (2017)
10.1038/modpathol.2017.126
Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer
Thomas A. Adams (2018)
10.1158/1078-0432.CCR-18-4011
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
J. Edwards (2019)
10.18632/ONCOTARGET.3216
Prognostic and predictive value of PDL1 expression in breast cancer
R. Sabatier (2015)
10.1080/2162402X.2018.1502128
TIM-3 expression in breast cancer
S. Burugu (2018)
10.1001/jamaoncol.2016.1061
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.
Sasha E Stanton (2016)
10.1111/imm.13001
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
10.1073/pnas.1811067116
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
J. Blando (2019)
10.5858/arpa.2013-0953-SA
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
A. Wolff (2014)
10.1080/2162402X.2018.1469594
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
10.1186/1741-7015-10-51
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
D. Altman (2012)
10.1186/s40425-016-0190-5
A New VISTA on combination therapy for negative checkpoint regulator blockade
J. Deng (2016)
10.3322/caac.21551
Cancer statistics, 2019
R. Siegel (2019)
10.1007/s13277-016-5010-5
c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer
X. Ren (2016)
10.1158/1078-0432.CCR-17-2542
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
F. Villarroel‐Espíndola (2017)
10.1093/annonc/mdu450
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R. Salgado (2015)
10.1007/s00262-018-2227-8
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
S. Xie (2018)
10.1038/s41598-018-27521-y
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
Ádám Nagy (2018)
10.1007/s00262-019-02434-5
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
Liju Zong (2019)
10.1007/s00262-018-2169-1
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative 1446 Cancer Immunology, Immunotherapy (2020) 69:1437–1446 1 3 breast cancer
TA Adams (2018)
10.1007/s00262-017-1968-0
Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma
L. Wu (2017)
The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs
R Salgado (2015)
10.1111/his.13882
PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia
Liju Zong (2019)
10.1093/annonc/mdx557
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
S. Burugu (2017)
10.1038/nm.4308
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
10.7150/jca.28134
Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets
Junjun Yang (2019)
10.1038/s41586-019-1674-5
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston (2019)
10.1073/pnas.1420370112
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
10.1080/2162402X.2017.1293215
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Christine Böger (2017)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1056/NEJMc1900150
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
H. O'Sullivan (2019)
10.1080/2162402X.2019.1581546
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
H. Loeser (2019)
The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group
R Salgado (2014)
10.1186/s13045-018-0684-3
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
Zihai Li (2018)
10.1186/s12885-018-4435-1
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
M. Zhang (2018)
10.18632/oncotarget.5583
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
T. Qin (2015)
10.3322/canjclin.39.6.399
Cancer statistics
N. Dubrawsky (1989)
10.1007/s10549-019-05387-6
HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
Y. Liu (2019)
10.1038/s41416-018-0313-5
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar